EPISODE · Oct 13, 2022 · 18 MIN
S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors
from OncLive® On Air · host OncLive® On Air
Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and other solid tumors.
Embed this episode
NOW PLAYING
S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors
0:00
18:43
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of OncLive® On Air?
This episode is 18 minutes long.
When was this OncLive® On Air episode published?
This episode was published on October 13, 2022.
Can I download this OncLive® On Air episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!